VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Increase in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 570,467 shares, a growth of 1,070.7% from the July 15th total of 48,730 shares. Based on an average trading volume of 8,475,803 shares, the short-interest ratio is currently 0.1 days. Currently, 16.7% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

VivoSim Labs Trading Down 0.9%

VIVS traded down $0.00 during midday trading on Thursday, reaching $0.33. The company’s stock had a trading volume of 398,514 shares, compared to its average volume of 2,898,351. VivoSim Labs has a 1 year low of $0.31 and a 1 year high of $5.30. The stock’s 50-day moving average is $0.80 and its 200-day moving average is $1.38. The firm has a market capitalization of $1.15 million, a price-to-earnings ratio of -0.06 and a beta of 1.47.

VivoSim Labs (NASDAQ:VIVS) last released its earnings results on Wednesday, August 12th. The company reported ($0.25) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter. VivoSim Labs had a negative net margin of 10,567.17% and a negative return on equity of 277.62%.

Institutional Investors Weigh In On VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP bought a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs at the end of the most recent quarter. Institutional investors and hedge funds own 8.23% of the company’s stock.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.